Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
pembrolizumab + bevacizumab
- Development stage
- Unknown
- Lead developer
- Merck
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Pembrolizumab + bevacizumab is a combination of two monoclonal antibody drugs used primarily in oncology. Pembrolizumab (Keytruda), developed by Merck, is an immune checkpoint inhibitor targeting the programmed cell death protein 1 (PD-1) receptor on T cells, thereby enhancing anti-tumor immune responses. Bevacizumab (Avastin), developed by Genentech/Roche, is a vascular endothelial growth factor A (VEGF-A) inhibitor that blocks angiogenesis, the formation of new blood vessels necessary for tumor growth and metastasis. The combination has been studied and used in various cancers including non-small-cell lung cancer, metastatic kidney cancer, ovarian cancer, and cervical cancer. Clinical studies have shown that this combination can improve progression-free survival and overall response rates compared to monotherapy or standard regimens[1][2][4][5][8].
- Brand names
- KeytrudaAvastin
- Other names
- pembrolizumabbevacizumabpembrobeva
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)VEGFA (Vascular endothelial growth factor A)
Beyond the preview
Go deeper on pembrolizumab + bevacizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on pembrolizumab + bevacizumab.